Table III.
Neurologic adverse events that were possibly, probably or definitely attributed to IT topotecan in 20 eligible patients*
| Event | Grade | |||
|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |
| Arachnoiditis | 1 | 1 | - | - |
| Ataxia | 1 | - | 1 | - |
| Depression | - | 1 | - | - |
| Diplopia / blurred vision | - | 2 | - | |
| Dizziness/lightheadedness | 1 | - | - | - |
| Involuntary movement / restlessness | 1 | - | - | - |
| Facial weakness/droop | 1 | - | ||
| Headache | 2 | 6 | 1 | - |
| Insomnia | - | 1 | - | - |
| Leukoencephalopathy | 1 | - | - | - |
| Motor neuropathy | 1 | - | 1 | - |
| Muscle weakness | 1 | - | 1 | |
| Seizures (olfactory) | - | - | 1 | - |
| Sensory neuropathy | - | 1 | - | - |
| Speech impairment | - | 1 | 1 | - |
*
More than 1 event may have occurred in the same patient